Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study...

Related Keywords

Virginia ,United States ,Chicago ,Illinois ,American ,Bortezomib Melphalan ,Douglasw Sborov ,Velcade Melphalan ,Velcade Bortezomib Melphalan ,Imran Khan ,Christie Corbett ,Amgen ,Myeloma Program ,Janssen Biotech Inc ,University Of Utah ,Janssen Research Development ,Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,National Library Of Medicine ,European Myeloma Network ,American Cancer Society ,None Of The Janssen Pharmaceutical Companies ,Hematology At Janssen Scientific Affairs ,Huntsman Cancer Institute ,International Myeloma Society ,Exchange Commission ,Companies Of Johnson ,International Myeloma Society Annual Meeting ,Johnson ,Multiple Myeloma Program ,Medical Affairs ,Janssen Scientific Affairs ,Janssen Biotech ,Interference With Serological ,With Determination ,Pharmaceutical Companies ,Infectious Diseases ,Janssen Research ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Plus Lenalidomide ,Final Analysis ,Prescribing Information ,Annual Meeting ,American Society ,Clinical Oncology ,Study Comparing Daratumumab ,Dexamethasone With Lenalidomide ,Refractory Multiple ,National Library ,Participants With Relapsed ,Evaluate Daratumumab ,Velcade Melphalan Prednisone ,Comparing Daratumumab ,Participants With Previously Untreated Multiple ,Combination With ,High Dose Therapy ,Asia Pacific Region ,Compare Progression Free Survival Btw ,Patients With Relapsed ,Statistics About Multiple Myeloma ,Accessed August ,The Janssen Pharmaceutical Companies Of Johnson Amp ,